For citations:
Orlova R.V., Vakhitova A.A., Topuzov E.E., Gluzman M.I., Serikova E.L., Petrenko M.A., Bembeeva L.V., Krasnoperova A.V., Kotkova T.N., Androsova A.V., Sharvashidze I.O. Tolerability of dose-dense and standard regimens of neoadjuvant chemotherapy in estrogen receptor-positive/HER2-negative breast cancer: results of a prospective observational study. Supportive Therapy in Oncology. 2024;1(3):13-25. (In Russ.) https://doi.org/10.17650/3034-2473-2024-1-3-13-25